07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Watchman Left Atrial Appendage: Completed Phase III enrollment

Boston Scientific completed enrollment of 407 high-risk AF patients in the open-label, U.S. Phase III PREVAIL trial comparing Watchman Left Atrial Appendage (LAA) Closure Technology vs. long-term warfarin therapy. The device has CE mark approval...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

Atritech, Boston Scientific deal

Boston Scientific completed its previously announced acquisition of cardiovascular device company Atritech for $100 million in cash up front, plus up to $275 million in regulatory and revenue milestones (see BioCentury, Jan. 24). Atritech Inc....
08:00 , Jan 24, 2011 |  BC Week In Review  |  Company News

Atritech, Boston Scientific deal

Boston Scientific will acquire cardiovascular device company Atritech for $100 million in cash up front, plus up to $275 million in regulatory and revenue milestones through 2015. Boston Scientific will gain Atritech's Watchman Left Atrial...
01:16 , Jan 20, 2011 |  BC Extra  |  Company News

Boston Scientific buying Atritech

Boston Scientific Corp. (NYSE:BSX) will acquire cardiovascular device company Atritech Inc. (Plymouth, Minn.) for $100 million in cash up front, plus up to $275 million in regulatory and revenue milestones through 2015. Boston Scientific will...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Watchman regulatory update

Atritech said FDA requested an additional confirmatory study for the Watchman Left Atrial Appendage (LAA) closure device prior to approval. The study, which is planned for this year, will evaluate the product in patients with...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Clinical News

Watchman: Phase II/III data

In the open-label, international Phase II/III PROTECT AF trial in 707 patients, Watchman plus warfarin produced a non-inferior 32% reduction in the primary efficacy endpoint of all stroke, CV and unexplained death and systemic embolization...